Olokizumab)OKZ; CDP 6038), an anti-IL-6 mAb obtained after humanization of antibody 132E09 produced in immune rats, exerts inhibitory activity by binding to IL-6 at site3 (Kd = 10 pM) to block the gp130 signaling that forms hexamers, showing significant anti-inflammatory effects in arthritis models (197), which is currently in the clinical stage of the treatment of RA. This evidence concerns the gene IL6 and rheumatoid arthritis.